Cure8 research brief
Researchers and clinicians want biomarkers that predict outcome or tailor treatment. This study suggests a mucosal gene-expression score is prognostic and declines in responders, but it does not yet show the score changes who benefits from biologic therapy.
Clinicians, researchers, and patients on biologics interested in biomarker-driven prognostication and trial-based molecular analyses.
The paper analyzed public trial datasets to separate prognostic association (score predicts outcome regardless of treatment) from treatment-effect modification (score changes who benefits). Across seven treated cohorts higher baseline score was linked with worse outcomes, and paired samples showed responders had larger declines in the score over time.
Randomized interaction analyses in three active-versus-placebo trials produced interaction estimates below 1 but with wide confidence intervals crossing 1, so they do not establish that the score changes relative treatment benefit.
The authors note limited donor numbers in some compartment analyses and call for prospective independent validation before clinical use.
Findings are based on re-analysis of public trial datasets and an abstract-level summary; randomized interaction tests were inconclusive and the authors state prospective independent validation is needed before clinical use.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This paper explores whether polygenic risk scores (PRS) predict key long-term outcomes after IBD diagnosis — notably intestinal surgery — which could be relevant for risk stratification research and future clinical tools...
The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
